Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).

Authors: Heinrich, Michael C., Somaiah, Neeta, Trent, Jonathan C., Wilky, Breelyn A., Burgess, Melissa Amber, Singh, Arun S., Attia, Steven, Agulnik, Mark, Tap, William D., Bauer, Sebastian, Jones, Robin Lewis, Serrano, Cesar, Zou, Liangxing, Moynihan, Kevin, Lawrence, Julia, Wagner, Andrew J.

Source: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, pTPS766-TPS766, 42p

Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES).

Authors: Chawla, Sant P., Falchook, Gerald Steven, Burgess, Melissa Amber, Chen, James Lin, Jones, Robin Lewis, Chua, Victoria S., Tapia, Coya, Ainscough, Jessica, Hamlett, Anthony, Merchant, Melinda S., Chugh, Rashmi

Source: Journal of clinical oncology. 39(15 suppl):11563-11563

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173107127.0x000001&indx=1&recIds=ETOCvdc_100173107127.0x000001

Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).

Authors: Naqash, Abdul Rafeh, O'Sullivan Coyne, Geraldine Helen, Moore, Nancy, Sharon, Elad, Takebe, Naoko, Fino, Kristin K., Ferry-Galow, Katherine V., Hu, James S., Van Tine, Brian Andrew, Burgess, Melissa Amber, Read, William L., Riedel, Richard F., George, Suzanne, Glod, John, Conley, Anthony Paul, Foster, Jared C., Fogli, Laura K., Parchment, Ralph E., Doroshow, James H., Chen, Alice P.

Source: Journal of clinical oncology. 39(15 suppl):11519-11519

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173105897.0x000001&indx=1&recIds=ETOCvdc_100173105897.0x000001

P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).

Authors: Schuetze, Scott, Ballman, Karla V., Ganjoo, Kristen N., Davis, Elizabeth J., Morgan, Jeffrey A., Tinoco, Gabriel, Burgess, Melissa Amber, Van Tine, Brian Andrew, Choy, Edwin, Shepard, Dale Randall, Kelly, Ciara Marie, Riedel, Richard F., von Mehren, Margaret, Siontis, Brittany L, Attia, Steven, Schwartz, Gary K., Deshpande, Hari Anant, Kozlowski, Erin, Chen, Helen X., Rubin, Brian

Source: Journal of clinical oncology. 39(15 suppl):11503-11503

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173105516.0x000001&indx=1&recIds=ETOCvdc_100173105516.0x000001

NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.

Authors: Ingham, Matthew, Allred, Jacob B., Gano, Katherine, George, Suzanne, Attia, Steven, Burgess, Melissa Amber, Seetharam, Mahesh, Boikos, Sosipatros Alexandros, Bui, Nam, Chen, James Lin, Close, Julia Lee, Cote, Gregory Michael, Thaker, Premal H., Ivy, S. Percy, Das, Biswajit, Shapiro, Geoffrey, Kochupurakkal, Bose, Trepel, Jane B., Pommier, Yves, Schwartz, Gary K.

Source: Journal of clinical oncology. 39(15 suppl):11506-11506

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173105556.0x000001&indx=1&recIds=ETOCvdc_100173105556.0x000001

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

NOTOS: A pivotal study of navtemadlin, a first-in-class mouse double minute 2 inhibitor (MDM2i), in patients (pts) with TP53 wild-type (TP53 WT) Merkel cell carcinoma (MCC) for whom anti PD-1/L1 therapy has failed.

Authors: Wong, Michael K.K., Burgess, Melissa Amber, Chandra, Sunandana, Fecher, Leslie Anne, Gaudy-Marqueste, Caroline, Silk, Ann W., Hanna, Glenn J., Lebbe, Celeste, Quéreux, Gaëlle, Rabinowits, Guilherme, Schadendorf, Dirk, Dutriaux, Caroline, Berking, Carola, Martin Liberal, Juan, Ascierto, Paolo Antonio, Houlihan, Emily, Steinmann, Kim, Chan, Tiffanie, Rothbaum, Wayne P., Kelly, Ciara Marie

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS9600-TPS9600, 1p

A phase 2 study of an anti–PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma.

Authors: Salkeni, Mohamad Adham, Ko, Brian, Van Tine, Brian Andrew, Conley, Anthony Paul, Davis, Elizabeth J., Burgess, Melissa Amber, Close, Julia Lee, Foster, Jared C., O'Sullivan Coyne, Geraldine Helen, Moore, Nancy, Fino, Kristin K., Ferry-Galow, Katherine V., Rosenberger, Christina, Parchment, Ralph E., Sharon, Elad, Doroshow, James H., Chen, Alice P.

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p11533-11533, 1p

ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.

Authors: Lacuna, Kristine Peregrino, Lee, Shing M, Ge, Liner, Druta, Mihaela, Conley, Anthony Paul, Keohan, Mary Louise, Agulnik, Mark, Burgess, Melissa Amber, Chalmers, Anna Weinberg, D'Amato, Gina Z., Powers, Benjamin, Seetharam, Mahesh, Siontis, Brittany L, Weiss, Mia C., Bose, Sminu, Sheikh, Tahir, Piekarz, Richard, Schwartz, Gary K., Ingham, Matthew

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p11531-11531, 1p

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.